Remote Observational Research for Multiple Sclerosis
A Natural Experiment
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 7, 2022
- Accepted in final form April 10, 2022
- First Published December 30, 2022.
Author Disclosures
- Riley Bove, MD,
- Shane Poole, BS,
- Richard Cuneo, MD,
- Sasha Gupta, MD,
- Joseph Sabatino Jr, MD, PhD,
- Meagan Harms, BA,
- Tifffany Cooper, BA,
- William Rowles, BA,
- Nicolette Miller, BS,
- Refujia Gomez, BA,
- Robin Lincoln, BS,
- Kira McPolin, BA,
- Kyra Powers, BA,
- Adam Santaniello, PhD,
- Adam Renschen, BS,
- Carolyn J. Bevan, MD, MS,
- Jeffrey M. Gelfand, MD, MAS,
- Douglas S. Goodin, MD,
- Chu-Yueh Guo, MD,
- Andrew R. Romeo, MD,
- Stephen L. Hauser, MD and
- Bruce Anthony Campbell Cree, MD, PhD on behalf of the UCSF MS-EPIC Team
- Riley Bove, MD,
(1) Sanofi Genzyme<br><br><br><br>(2) Novartis<br><br><br><br>(3) EMD Serono<br><br><br><br>(4) Alexion<br><br><br><br>(5) TG Therapeutics<br><br><br><br>(6) Janssen<br><br><br><br>(7) Horizon
NONE
None
NONE
NONE
NONE
NONE
(1) Sanofi Genzyme<br><br><br><br>(2) Novartis<br><br><br><br>(3) EMD Serono<br><br><br><br>(4) Alexion<br><br><br><br>(5) Horizon<br><br><br><br>(6) TG Therapeutics<br><br><br><br>(7) Janssen
NONE
NONE
NONE
(1) Commercial entity, F Hoffmann Laroche<br><br><br><br>(2) Commercial entity, Biogen<br><br><br><br>(3) Commercial entity, Novartis
NIH NLM R01LM013396 Sep 1, 2021 - May 31, 2025<br><br><br><br>Role: PI<br><br><br><br><br><br><br><br>DOD MSRP CTA Award 2022-2025
(1) UCSF Medical staff (10/2015-current)
(1) National MS Society, Career Transition Award<br><br><br><br>(2) National MS Society, Research Award<br><br><br><br>(3) National MS Society, Harry Weaver Award
NONE
NONE
NONE
NONE
NONE
NONE
- Shane Poole, BS,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Richard Cuneo, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sasha Gupta, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Husband received funding for his PhD work from NASA
NONE
I received funding from my fellowship from the National MS <br>Society and Alpha-Stem Cell-CIRM foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Joseph Sabatino Jr, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis Pharmaceuticals<br>Roche/Genentech
NIH, K08NS107619, PI, year 4
NONE
National Multiple Sclerosis society, TA-1903-33713 and RG-<br>2110-38434
NONE
NONE
NONE
NONE
NONE
NONE
- Meagan Harms, BA,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Tifffany Cooper, BA,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- William Rowles, BA,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolette Miller, BS,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Refujia Gomez, BA,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Robin Lincoln, BS,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kira McPolin, BA,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kyra Powers, BA,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Adam Santaniello, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Adam Renschen, BS,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Carolyn J. Bevan, MD, MS,
Ad board for Genentech
NONE
(1) Genentech - compensated travel for speaking at a <br><br><br><br>conference.
NONE
NONE
NONE
NONE
NONE
(1) Genentech
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey M. Gelfand, MD, MAS,
DSMB for a National Institutes of Aging funded study. Service on trial steering <br>committees for Genentech/Roche.
NONE
None
Dr. Gelfand is on the editorial advisory board of Neurology: Neuroimmunology & <br><br>Neuroinflammation. Dr. Gelfand's spouse is Editor-in-Chief of Headache and <br><br>previously served on the editorial team of JAMA Neurology.
NONE
Honoraria from UpToDate (Dr. Gelfand and spouse)
NONE
Consulting for Biogen. His spouse has received prior consulting fees from <br><br>Biohaven, Advanced Clinical, Theranica, and Satsuma.
NONE
NONE
NONE
Research support to University of California, San Francisco from Genentech / <br>Roche and Vigil Neuroscience. His spouse has received grant support from <br>Amgen.
NONE
NONE
PI of an Institutional Clinician Training Award from the National MS Society.
NONE
NONE
NONE
NONE
NONE
Dr. Gelfand has received compensation for medical-legal consulting as an expert <br>witness, including for the United States Vaccine Injury Compensation Program.
- Douglas S. Goodin, MD,
None
NONE
Occasional community lectures, symposia and/or<br><br><br><br>academic talks sponsored by (1) Horizon, <br><br><br><br>(2) Biogen. In many cases, travel costs were reimbursed.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Chu-Yueh Guo, MD,
(1) Serving on a scientific advisory board for Genentech
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew R. Romeo, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH-NINDS, U01 NS106670, investigator, 2021-present
NONE
(1) National Multiple Sclerosis Society (Institutional <br>Clinical Training Award)
NONE
NONE
NONE
NONE
NONE
NONE
- Stephen L. Hauser, MD and
Serves on scientific advisory board for (1) Accure, (2) <br>Alector, and (3) Annexon; serves on Board of Directors <br>for (4) Neurona.
NONE
None
NONE
NONE
(1) Harrison's Principles of Internal Medicine,<br>McGraw-Hill Education
NONE
(1) NGM Bio
NONE
(1) F. Hoffmann La Roche, (2) Novartis AG; travel <br>reimbursement and writing support for anti-CD20 related <br>meetings and presentations.
NONE
NONE
(1) NIH, R35NS111644, PI
NONE
(1) Valhalla Foundation
Stock options received for service on board of directors <br>for (1) Neurona
NONE
NONE
NONE
Stock options received for service on scientific advisory <br>board for (1) Accure, (2) Alector, (3) Annexon
NONE
- Bruce Anthony Campbell Cree, MD, PhD on behalf of the UCSF MS-EPIC Team
Data safety monitoring board: Immunic AG
NONE
None
NONE
NONE
NONE
NONE
Alexion, Atara, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, <br>Gossamer Bio, Hexal/Sandoz, Horizon, Neuron23, Novartis, Sanofi, Siemens, TG <br>Therapeutics
NONE
NONE
NONE
Genentech
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the UCSF Weill Institute for Neuroscience, Division of Neuroimmunology and Glial Biology, Department of Neurology, University of California San Francisco, San Francisco, CA.
- Correspondence
Dr. Bove riley.bove{at}ucsf.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.